Access

Letter

Nature 450, 712-716 (29 November 2007) | doi:10.1038/nature06261; Received 3 August 2007; Accepted 17 September 2007

Open Innovation Challenges

naturejobs

Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes

Jill C. Milne1,4, Philip D. Lambert1,4, Simon Schenk2,4, David P. Carney1, Jesse J. Smith1, David J. Gagne1, Lei Jin1, Olivier Boss1, Robert B. Perni1, Chi B. Vu1, Jean E. Bemis1, Roger Xie1, Jeremy S. Disch1, Pui Yee Ng1, Joseph J. Nunes1, Amy V. Lynch1, Hongying Yang1, Heidi Galonek1, Kristine Israelian1, Wendy Choy1, Andre Iffland1, Siva Lavu1, Oliver Medvedik1, David A. Sinclair3, Jerrold M. Olefsky2, Michael R. Jirousek1, Peter J. Elliott1 & Christoph H. Westphal1

  1. Sirtris Pharmaceuticals Inc., 790 Memorial Drive, Cambridge, Massachusetts 02139, USA
  2. Division of Endocrinology and Metabolism, Department of Medicine, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093, USA
  3. Department of Pathology, Paul F. Glenn Laboratories for the Biological Mechanisms of Aging, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, Massachusetts 02115, USA
  4. These authors contributed equally to this work.

Correspondence to: Christoph H. Westphal1 Correspondence and requests for materials should be addressed to C.H.W. (Email: cwestphal@sirtrispharma.com).

Top

Calorie restriction extends lifespan and produces a metabolic profile desirable for treating diseases of ageing such as type 2 diabetes1, 2. SIRT1, an NAD+-dependent deacetylase, is a principal modulator of pathways downstream of calorie restriction that produce beneficial effects on glucose homeostasis and insulin sensitivity3, 4, 5, 6, 7, 8, 9. Resveratrol, a polyphenolic SIRT1 activator, mimics the anti-ageing effects of calorie restriction in lower organisms and in mice fed a high-fat diet ameliorates insulin resistance, increases mitochondrial content, and prolongs survival10, 11, 12, 13, 14. Here we describe the identification and characterization of small molecule activators of SIRT1 that are structurally unrelated to, and 1,000-fold more potent than, resveratrol. These compounds bind to the SIRT1 enzyme–peptide substrate complex at an allosteric site amino-terminal to the catalytic domain and lower the Michaelis constant for acetylated substrates. In diet-induced obese and genetically obese mice, these compounds improve insulin sensitivity, lower plasma glucose, and increase mitochondrial capacity. In Zucker fa/fa rats, hyperinsulinaemic-euglycaemic clamp studies demonstrate that SIRT1 activators improve whole-body glucose homeostasis and insulin sensitivity in adipose tissue, skeletal muscle and liver. Thus, SIRT1 activation is a promising new therapeutic approach for treating diseases of ageing such as type 2 diabetes.

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

NEWS AND VIEWS

Medicine Grapes versus gluttony

Nature News and Views (16 Nov 2006)